Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by a loss of the neurons that control voluntary movements. Patients lose muscle strength and in the final stages of the disease are unable to move and have difficulty swallowing and breathing. Recent advances have been made in understanding the molecular mechanisms that contribute to ALS. In contrast, little progress has been made in drug discovery - none of over 30 new drugs tested in ALS has been found to be effective, and median survival from diagnosis remains at 2-3 years. The purpose of this project, which is the continuation of an ongoing NIH supported study, is to search for clues for novel treatments by i) studying in large populations of individuals who have been followed for many years how the individuals who develop ALS are different from those who remain healthy;and ii) examining among individuals with ALS whether there are factors that predict a slower disease progression. During the past 5 years of this project, we have found that ALS risk was inversely associated with long term intakes of vitamin E and other antioxidants, and positively associated with cigarette smoking. In parallel, preliminary evidence emerged that blood levels of urate, a potent antioxidant, are inversely related to the rate of ALS progression - this is encouraging in view of urate's strong antioxidant properties, its robust inverse associations with both risk and progression of Parkinson disease, and the fact that urate concentrations can be increased by administration of inosine (a urate precursor) or other available drugs. Building on these findings, this proposal will address two key questions - whether plasma levels of urate in apparently healthy individuals contribute to predict their ALS risk, and whether plasma levels of urate among patients at an early stage of ALS contribute to predict their rate of clinical progression. Additionally, we will examine the role of other plasma antioxidants in relation to ALS risk, and we will conduct a discovery study for novel risk markers using a metabolomic approach. The proposed aims of our study stand to identify or substantiate major new contributors to ALS, with realistic prospects for mechanistic insight and therapeutic impact. Key strengths of our proposal include: 1) availability for the first time of blood samples collected before the onset of ALS;2) use of an independently funded large randomized trial to study ALS progression;3) interdisciplinary expertise of our research team.

Public Health Relevance

Amyotrophic lateral sclerosis (ALS) is an incurable progressive neurodegenerative disease characterized by a loss of the neurons that control voluntary movements. One of the molecular mechanisms that seems to contribute to ALS is oxidative stress, therefore, the primary focus of the proposed project is to examine in large ongoing longitudinal studies whether plasma levels of urate and other antioxidants collected from apparently healthy individuals contribute to predict their ALS risk, and whether plasma levels of urate among patients at an early stage of ALS contribute to predict their rate of clinica progression. A further aim is the exploration of other plasma metabolites that may be related to ALS risk and progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS045893-09
Application #
8685338
Study Section
Neurological, Aging and Musculoskeletal Epidemiology Study Section (NAME)
Program Officer
Gubitz, Amelie
Project Start
2003-04-01
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Harvard University
Department
Nutrition
Type
Schools of Public Health
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Ascherio, Alberto; O'Reilly, Eilis Joan (2016) New insights on physical activity and amyotrophic lateral sclerosis. Eur J Epidemiol 31:213-5
Hagan, Kaitlin A; Munger, Kassandra L; Ascherio, Alberto et al. (2016) Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses' Health Study. Am J Public Health 106:1650-5
Fitzgerald, Kathryn C; O'Reilly, Éilis J; Falcone, Guido J et al. (2014) Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol 71:1102-10
Fondell, Elinor; O'Reilly, Eilis J; Fitzgerald, Kathryn C et al. (2014) Dietary fiber and amyotrophic lateral sclerosis: results from 5 large cohort studies. Am J Epidemiol 179:1442-9
Fondell, Elinor; O'Reilly, Eilis J; Fitzgerald, Kathryn C et al. (2013) Magnesium intake and risk of amyotrophic lateral sclerosis: results from five large cohort studies. Amyotroph Lateral Scler Frontotemporal Degener 14:356-61
O'Reilly, Éilis J; Wang, Hao; Weisskopf, Marc G et al. (2013) Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14:205-11
Fitzgerald, Kathryn C; O'Reilly, Eilis J; Fondell, Elinor et al. (2013) Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies. Ann Neurol 73:236-45
Fondell, Elinor; O'Reilly, Eilis J; Fitzgerald, Kathryn C et al. (2012) Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler 13:573-9
Wang, Hao; O'Reilly, Éilis J; Weisskopf, Marc G et al. (2011) Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol 68:207-13
Simon, Kelly Claire; Gao, Xiang; Chen, Honglei et al. (2010) Calcium channel blocker use and risk of Parkinson's disease. Mov Disord 25:1818-22

Showing the most recent 10 out of 17 publications